(EMAILWIRE.COM, March 14, 2022 ) Gulf Countries Oncology Market size is estimated to reach $5.1 billion by 2027, growing at a CAGR of 11.2% during the forecast period 2022-2027. The gulf countries like the United Arab Emirates, Bahrain, Saudi Arabia, Oman, Qatar, and Kuwait, matured breast cancer, colorectal cancer, leukemia, thyroid cancer, and non-Hodgkin lymphomas are the most typical cancers prevailing among younger communities in comparison with other countries. The increasing predominance of cancer in the Gulf countries has been largely attributed to tobacco smoking in 2018. Typical treatment techniques for cancer include chemotherapy, immunotherapy, and radiation therapy. With the onset of biomarkers, there is a considerable boost in targeted, small molecule, and biologic therapies. Chemotherapy persists in being the backbone of cancer treatment and is available to nearly all patients in the Gulf countries. The unsupportive changes in lifestyle and the surging tobacco smoking is set to drive the Gulf Countries Oncology Market resulting in a greater count of cancer cases. The minimized physical activity and heightening intake of unhealthy food are set to propel the growth of the Gulf Countries Oncology Market during the forecast period 2022-2027. This represents the Gulf Countries Oncology Industry Outlook.
Gulf Countries Oncology Market Segment Analysis By Therapeutic Type:
The Gulf Countries Oncology Market based on therapeutic type can be further segmented into Chemotherapy, Immunotherapy, Targeted Therapy, Stem Cell Transplant, and Others. The Targeted Therapy Segment held the largest market share in 2021. This growth is owing to the increased application of targeted therapy in the treatment of cancer in conjunction with chemotherapy. The heightening utilization of biomarker levels by healthcare professionals to determine ailment hazards and actualize an anti-cancer plan in terms of analysis, prediction, and selection of targeted therapy are further propelling the growth of the targeted therapy segment.
Furthermore, the Chemotherapy segment is estimated to grow with the fastest CAGR of 12.1% during the forecast period 2022-2027 owing to chemotherapy being the foundation of cancer treatment and is available to nearly all patients.
Gulf Countries Oncology Market Segment Analysis By Therapeutic Application Area:
The Gulf Countries Oncology Market based on therapeutic application area can be further segmented into Blood Cancer, Lung Cancer, Breast Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Gastrointestinal Cancer, and Others. The Breast Cancer Segment held the largest market share in 2021. This growth is owing to the high incidence of breast cancer among the younger communities in the Gulf countries when compared to other countries of the world. The reduced physical activity increased awareness campaigns, and an upsurge in tobacco smoking is further propelling the growth of this segment.
Furthermore, the Colorectal Cancer segment is estimated to grow with the fastest CAGR of 12.3% during the forecast period 2022-2027 owing to the increased tobacco smoking and developments of errors in the DNA of healthy cells. The intake of unhealthy food is further propelling the growth of the Colorectal Cancer segment.
Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=18427
Report Price: $ 4300 (Single User License)
Gulf Countries Oncology Market Segment Analysis By Country:
The Gulf Countries Oncology Market based on the country can be further segmented into Bahrain, Kuwait, Oman, Qatar, Kingdom of Saudi Arabia, United Arab Emirates, and Others. Kingdom of Saudi Arabia (Gulf Countries Oncology Market) held the largest share of the overall market in 2021. The growth of this region is owing to the increasing predominance of cancer in the region. The changes in lifestyle brought in by accelerated modernization and urbanization resulting in greater per capita intake of meat and processed food in conjunction with soaring tobacco smoking are propelling the growth of the Gulf Countries Oncology Market in the Kingdom of Saudi Arabia region.
Furthermore, the Qatar region is estimated to be the region with the fastest CAGR of 12.5% over the forecast period 2022-2027. This growth is owing to factors like surging initiatives to enhance cancer awareness and enhanced screening of patients in the region. The increased tobacco smoking is fuelling the progress of the Gulf Countries Oncology Market in the Qatar region.
Gulf Countries Oncology Market Drivers
Increased Initiatives To Enhance Awareness Of Cancer Are Projected To Drive The Growth Of Gulf Countries Oncology Market:
The predominance of cancer in the Gulf countries has been greatly ascribed to tobacco smoking. There have been numerous initiatives in the gulf countries to enhance the awareness of cancer. In October 2021, Procter & Gamble (P&G) associated with Zulekha Hospital in the UAE and Choithrams for the Pink, It Now campaigns as part of Breast Cancer Awareness month. This initiative aims to raise awareness of the ailment, advance screening, and early testing, and organize funds for research into its cause, prevention, diagnosis, treatment, and cure. On purchases of Dh70 of P&G products like Pampers, Tide, Ariel, and Herbal Essences at Choithrams, purchasers will acquire a free breast cancer consultation and mammogram. Similarly, Qatar Cancer Society (QCS), in collaboration with Qatar Cyclists Centre, coordinated the Pink Ride event with the target of spreading awareness of breast cancer, the techniques of prevention, and early discovery. These kinds of initiatives are fuelling the growth of the Gulf Countries Oncology Market during the forecast period 2022-2027.
Novel Launches And Inclination Towards Targeted Therapies Are Expected To Boost The Demand Of Gulf Countries Oncology:
With the arrival of biomarkers, there is a considerable boost in targeted, small molecule, and biologic therapies. Chemotherapy persists in being the backbone of cancer treatment and is readily available to nearly all patients. There is a robust oncology pipeline in development with numerous late-stage next-generation Biotherapeutics and many immuno-oncology therapies presently in development across all stages. Gulf countries have become considerably accessible with inspiring accomplishments in terms of cancer drugs authorizations since 2015. The greatest count of authorizations was observed in Saudi Arabia and Lebanon. UAE comes first among the Gulf countries in the acceptance of novel checkpoint inhibitors. These kinds of advancements are driving the growth of the Gulf Countries Oncology Market during the forecast period 2022-2027.
Direct Purchase @ https://www.industryarc.com/purchasereport.php?id=18427
Gulf Countries Oncology Market Challenges
Challenges In R&D And Impact Of COVID-19 Pandemic Are Hampering The Growth Of The Gulf Countries Oncology Market:
Oncology persists as the most demanding area for research and development, encountering considerable hazards of failure and lengthy duration. Obstacles to acceptance of novel drugs persist, delaying patient gain from treatment advances. As treatment alternatives become more including alternatives like immunotherapy, the effect on spending levels has evolved into a focal area across most parts of the globe, which is a trend that is anticipated to continue over the consequent five years with unceasing development. The gulf countries trail behind the developed world in terms of advancement in cancer care. Access to novel therapy in the Gulf countries is hard despite the rising predominance of cancer and proactive actions taken by the governments. The COVID pandemic has not only constrained accessible resources but has also influenced the early discovery of cancer as screening actions have taken a back-seat. These issues are hampering the growth of the Gulf Countries Oncology Market.
Gulf Countries Oncology Industry Outlook
Novel launches, mergers, and acquisitions switch towards targeted therapies, immune-oncology therapies, and next-generation biotherapeutics, robust oncology pipeline in development and greatest count of approvals are key strategies adopted by players in the Market. Gulf Countries Oncology top 10 companies include:
NUPCO, Kingdom of Saudi Arabia (KSA)
AbbVie Inc, UAE
Amgen, Gulf Countries (Saudi Arabia, UAE, Kuwait, Bahrain, Oman, and Qatar)
Astellas MEA
Roche, UAE
Johnson & Johnson, Middle East
Elekta Gulf, Kingdom of Saudi Arabia (KSA)
Varian Medical Systems Inc., Middle East
Accuray Incorporated, Middle East
Life Pharma, Middle East
Acquisitions/Product Launches:
In October 2021, Astellas Pharma commenced utilizing sugarcane-derived polyethylene as 50% of its raw material for building pharmaceutical blister packs. As per the firm, the move depicts the worlds first use of biomass plastic for drug blister packs. Astellas will begin utilizing the biomass-based plastic blister pack for its Irribow Tablet 5µg tablets on the Japanese market, which target diarrhea-predominant irritable bowel syndrome.
In October 2021, Roche declared that it has introduced the AVENIO Tumor Tissue CGP Kit. The Kit augments the present CGP portfolio provided by Roche and Foundation Medicine and permits laboratories to extend their oncology research in-house. Eventually, a forthcoming version of the kit can result in added resources for clinicians to utilize in the diagnosis and treatment of cancer.
In April 2021, Allergan Aesthetics, an AbbVie firm declared the introduction of SkinMedica® Neck Correct Cream, the earliest product from the professional-grade skin care line formulated to attend to the particular biology of the skin on the neck and décolleté area. SkinMedica® Neck Correct Cream was planned to avert the early signs and treat the visible countenance of moderate to serious neck aging. It is clinically proven to stabilize and stiffen the look of creepy skin, avert and minimize the look of baggy, level deep lines and wrinkles and improve skin tone evenness.
Key Takeaways
By country, the Kingdom of Saudi Arabia (KSA) (Gulf Countries Oncology Market) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the soaring high count of cancer patients requiring chemotherapy in the Kingdom of Saudi Arabia region.
Gulf Countries Oncology Market growth is being driven by the increasing population of the elderly and the proliferating knowledge regarding the ailment, diagnosis, and recording of cancer cases requiring chemotherapy. However, the lack of advancement in cancer care in comparison with the developed economies is one of the major factors hampering the growth of the Gulf Countries Oncology Market.
Gulf Countries Oncology Market Detailed Analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Gulf Countries Oncology Market report.
Related Report:
Oncology Market
https://www.industryarc.com/Report/18335/oncology-market.html
For more Lifesciences and Healthcare Market reports, please click here
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.
Discussion about this post